Table 1 Reimbursement approval year for indications of 13 anti-cancer drugs in 10 countries (as of February 3, 2013)
From: International comparison of the factors influencing reimbursement of targeted anti-cancer drugs
Drug | Indications | Countries | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Australia | Canada (Ontario) | France | Germany | Japan | Korea | Sweden | Taiwan | UK | US * | ||
Bevacizumab | Colorectal cancer : with irinotecan, fluorouracil, and leucovorin | No | 2009 | 2005 | 2009 | 2007 | No | No | 2011 | No | 2004 |
Colorectal cancer : with oxaliplatin, fluorouracil, and folinic acid | 2008 | 2009 | 2008 | 2009 | 2009 | No | No | No | No | 2006 | |
NSCLC : 1st line with platinum-based chemotherapy | No | No | 2008 | 2009 | 2009 | No | No | No | No | 2006 | |
Renal cell carcinoma : 1st line with interferon-α | No | No | 2008 | 2009 | No | No | No | No | No | 2009 | |
Cetuximab | Colorectal cancer : with irinotecan | 2010 | 2011 | 2009 | 2009 | 2008 | No | No | 2009 | No | 2004 |
Colorectal cancer (K-RAS wild type): 1st line with oxaliplatin, fluorouracil, and folinic acid | 2010 | No | 2009 | 2009 | 2010 | No | No | No | 2009 | 2012 | |
Head and neck cancer (squamous cell carcinoma) : 1st line with platinum-based chemotherapy | 2007 | 2011 | 2010 | No | No | No | No | 2009 | No | 2011 | |
Crizotinib | NSCLC (ALK fusion positive): 2nd line (vs. docetaxel) | No | No | No | No | No | No | No | No | No | 2011 |
Dasatinib | Chronic myeloid leukemia, chronic phase: 1st line | 2009 | 2008 | 2007 | No | 2009 | 2008 | 2011 | 2009 | No | 2010 |
Erlotinib | Pancreatic cancer : 1st line with gemcitabine | 2012 | No | No | No | 2011 | 2010 | No | No | No | 2005 |
Imatinib | Gastrointestinal stromal tumor: Adjuvant therapy | 2011 | 2008 | 2009 | No | No | 2010 | 2009 | 2011 | no | 2008 |
Lapatinib | Breast cancer with HER2 overexpression: 2nd line with capecitabine | No | No | 2008 | No | 2009 | 2010 | No | No | No | 2007 |
Lenalidomide | Multiple myeloma : 1st-line | No | 2009 | No | No | 2010 | No | 2008 | No | 2009 | 2006 |
Nilotinib | Chronic myeloid leukemia, chronic phase: 1st-line | 2011 | 2012 | 2008 | 2011 | 2010 | 2011 | 2008 | 2012 | 2012 | 2007 |
Pemetrexed | NSCLC: Maintenance treatment | No | 2008 | 2008 | No | 2009 | No | No | No | 2010 | 2009 |
NSCLC (for non-squamous histology): 1st line with cisplatin | 2009 | 2008 | 2008 | No | 2009 | 2010 | No | 2009 | 2009 | 2008 | |
Sorafenib | Liver cancer : 1st line | 2008 | 2008 | 2008 | 2009 | 2009 | 2011 | No | No | No | 2007 |
Sunitinib | Renal cell carcinoma : 1st line | 2010 | 2008 | 2006 | 2009 | 2008 | 2007 | 2006 | 2010 | 2009 | 2006 |
Temsirolimus | Renal cell carcinoma : 1st-line for poor prognosis patients | No | 2011 | 2008 | 2009 | 2010 | 2011 | No | No | No | 2007 |